Table 8. Disease characteristics.
Group A: conventional (non-chronomodulated) chemotherapy; Group B: chronomodulated chemotherapy
| Study | Primary site - colon:rectum (ratio) | Metastasis | Previous chemotherapy | Previous radiotherapy | Previous surgery | |||||
| Group A | Group B | Group A | Group B | Group A | Group B | Group A | Group B | Group A | Group B | |
| Ramanathan et al. 2008 [43] | 76:28 (2.7) | 16:9 (1.7) | Not specified | Not specified | Not specified | Not specified | ||||
| Huang et al. 2006 [46] | 14:6 (2.3) | 16:6 (2.6) | Liver metastasis >2 cm: 17 (85%). Both lobes: 12 | Liver metastasis >2 cm: 18 (81.8%). Both lobes: 16 | Not specified | Not specified | Not specified | |||
| Giacchetti et al. 2006 [44] | 213:69 (3) | 217:65 (3.3) | Three or more metastasis: 48 (17%) | Three or more metastasis: 38 (13%) | 48 (17%) | 54 (19%) | 18 (6%) | 26 (9%) | Surgery for metastasis: 14 (5%) | Surgery for metastasis: 14 (5%) |
| Garufi et al. 2006 [24] | 28:5 (5.6) | 28:7 (4) | Two or more: 10 (30%) | Two or more: 13 (37%) | 9 (27%) | 7 (20%) | 2 (6%) | 3 (9%) | Not specified | |
| Focan et al. 1999 [45] | 18:9 (2) | 23:6 (3.8) | Isolated liver metastasis: 22 (81.4%) | Isolated liver metastasis: 23 (79.3%) | 6 (22%) | 10 (34%) | 0 (0%) | 3 (10.3%) | 27 (100%) | 29 (100%) |
| Lévi et al. 1997 [29] | 66:27 (2.4) | 63:30 (2.1) | Less than three: 85 (91%) | Less than three: 85 (91%) | 11 (12%) | 10 (11%) | 7 (8%) | 6 (6%) | Surgery for metastasis: 7 (8%) | 22 (24%) |
| Lévi et al. 1994 [35] | 30:17 (1.76) | 34:11 (3.1) | Two or more: 20 (42.5%) | Two or more: 23 (51.1%) | 2 (4.2%) | 5 (11.1%) | 4 (8.5%) | 5 (11.1%) | Not specified | |